SpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Get Free Report) Director Daniel Lynch sold 400 shares of SpringWorks Therapeutics stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $60.00, for a total transaction of $24,000.00. Following the transaction, the director now owns 130,544 shares of the company's stock, valued at $7,832,640. This represents a 0.31 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Daniel Lynch also recently made the following trade(s):
- On Monday, February 10th, Daniel Lynch sold 175,000 shares of SpringWorks Therapeutics stock. The shares were sold at an average price of $54.46, for a total transaction of $9,530,500.00.
SpringWorks Therapeutics Price Performance
Shares of SpringWorks Therapeutics stock traded down $1.64 on Friday, reaching $58.29. 3,531,485 shares of the company traded hands, compared to its average volume of 2,747,973. SpringWorks Therapeutics, Inc. has a 52 week low of $28.21 and a 52 week high of $62.00. The company has a 50 day moving average of $41.10 and a 200 day moving average of $37.64. The firm has a market capitalization of $4.34 billion, a PE ratio of -15.02 and a beta of 0.81.
SpringWorks Therapeutics (NASDAQ:SWTX - Get Free Report) last released its earnings results on Thursday, February 20th. The company reported ($1.04) earnings per share for the quarter, missing analysts' consensus estimates of ($0.66) by ($0.38). SpringWorks Therapeutics had a negative net margin of 203.09% and a negative return on equity of 48.21%. The company had revenue of $61.55 million for the quarter, compared to the consensus estimate of $60.53 million. As a group, analysts anticipate that SpringWorks Therapeutics, Inc. will post -3.17 earnings per share for the current year.
Analyst Upgrades and Downgrades
A number of brokerages have recently issued reports on SWTX. HC Wainwright reiterated a "buy" rating and set a $74.00 price objective on shares of SpringWorks Therapeutics in a report on Friday. Evercore ISI boosted their price target on shares of SpringWorks Therapeutics from $60.00 to $65.00 and gave the stock an "outperform" rating in a report on Wednesday, February 12th. Guggenheim cut their price target on shares of SpringWorks Therapeutics from $80.00 to $78.00 and set a "buy" rating on the stock in a report on Wednesday, January 8th. Finally, Wedbush restated an "outperform" rating and set a $81.00 price target on shares of SpringWorks Therapeutics in a report on Thursday. Six research analysts have rated the stock with a buy rating, According to MarketBeat, the company has an average rating of "Buy" and an average target price of $71.50.
Get Our Latest Report on SWTX
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently modified their holdings of the stock. GF Fund Management CO. LTD. bought a new position in shares of SpringWorks Therapeutics during the 4th quarter valued at approximately $56,000. Palisades Investment Partners LLC grew its position in shares of SpringWorks Therapeutics by 9.9% during the 4th quarter. Palisades Investment Partners LLC now owns 134,445 shares of the company's stock valued at $4,857,000 after acquiring an additional 12,154 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in shares of SpringWorks Therapeutics by 19.4% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 119,052 shares of the company's stock valued at $4,301,000 after buying an additional 19,315 shares in the last quarter. Woodline Partners LP lifted its stake in shares of SpringWorks Therapeutics by 7.9% during the 4th quarter. Woodline Partners LP now owns 1,490,136 shares of the company's stock valued at $53,839,000 after buying an additional 108,512 shares in the last quarter. Finally, Zimmer Partners LP purchased a new stake in shares of SpringWorks Therapeutics during the 4th quarter valued at approximately $5,141,000.
About SpringWorks Therapeutics
(
Get Free Report)
SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.
Featured Articles
Before you consider SpringWorks Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and SpringWorks Therapeutics wasn't on the list.
While SpringWorks Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
